Research Project

Project Title:

MONET STUDY

Project Type:

Clinical Trial, Enrolment ongoing

Disease group(s):

Immune glomerulopathies

Project Summary:

This is an open-label, phase II study in which all participants will receive active treatment with MOR202 (felzartamab), for a total of nine doses during 24 weeks. Patients will be monitored up to month 24 from the first treatment.

Lead principal investigator(s):

Piero Ruggenenti, Bergamo

Co-investigator(s):

Imeraj Amantia, Bergamo
Matias Trillini, Bergamo

Project Period:

12/2021   -   12/2024

EudraCT Nr.:

2021-000835-30

« Back to research page